dermatology is our passion. what is yours - tfscro.com · dermatology is our passion. what is ......

SCIderm GmbH · Drehbahn 1 – 3 · D – 20354 Hamburg · www.SCIderm.com – 1 –

Dermatology is our passion. What is yours?

Publications Prof. Kristian reich, MD, PhD

original articles in peer-reviewed journals

1. Patient-relevant needs and treatment goals in nail psoriasis. Blome C, Costanzo A, Dauden E, Ferrandiz C, Girolomoni G, Gniadecki R, Iversen L, Menter A, Michaelis-Wittern K, Morita A, Nakagawa H, Reich K, Augustin M. Qual Life Res. 2015 Oct 3. [Epub ahead of print]

2. Patient-relevant treatment goals in psoriasis. Blome C, Gosau R, Radtke MA, Reich K, Rustenbach SJ, Spehr C, Thaçi D, Augustin M. Arch Dermatol Res. 2016 Mar;308(2):69-78. [Epub ahead of print]

3. Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled Phase 2a study. Ludbrook VJ, Hicks KJ, Hanrott KE, Patel JS, Binks MH, Wyres MR, Watson J, Wilson P, Simeoni M, Schifano LA, Reich K, Griffiths CE. Br J Dermatol. 2016 Jan 19. [Epub ahead of print]

4. Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials. Papp KA, Armstrong AW, Reich K, Karunaratne M, Valdecantos W. Am J Clin Dermatol. 2016 Feb;17(1):79-86.

5. A prospective phase 3, randomised, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Papp KA, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C, Toth D, Langley RG, Cather J, Gottlieb AB, Thaçi D, Krueger JG, Russell CB, Milmont CE, Li J, Klekotka PA, Kricorian G, Nirula A. Br J Dermatol. 2016 Feb 23. [Epub ahead of print]

6. Panimmunoglobulin and IgE-selective extracorporeal immunoadsorption in patients with severe atopic dermatitis. Reich K, Deinzer J, Fiege AK, von Gruben V, Sack AL, Thraen A, Weisenseel P, Breuer K, Jäckle S, Meier M. J Allergy Clin Immunol. 2016 Mar 15. [Epub ahead of print]

7. Oral alitretinoin treatment in patients with palmoplantar pustulosis inadequately responding to standard topical treatment: a randomised Phase II study. Reich K, Graff O, Mehta N. Br J Dermatol. 2016 Jan 22. [Epub ahead of print]

8. Retrospective data collection of psoriasis treatment with fumaric acid esters in children and adolescents in Germany (KIDS FUTURE study). Reich K, Hartl C, Gambichler T, Zschocke I. J Dtsch Dermatol Ges. 2016 Jan;14(1):50-7. [Epub ahead of print]



9. More on PML in Patients Treated with Dimethyl Fumarate. Reich K, Hartung HP, Lebwohl M. N Engl J Med. 2016 Jan 21;374(3):294-5. [Epub ahead of print]

10. Epidemiology and Comorbidity in Children with Psoriasis and Atopic Eczema. Augustin M, Radtke MA, Glaeske G, Reich K, Christophers E, Schaefer I, Jacobi A. Dermatology. 2015;231(1):35-40.

11. Development and Validation of a Melanoma Risk Score Based on Pooled Data from 16 Case-Control Studies. Davies JR, Chang YM, Bishop DT, Armstrong BK, Bataille V, Bergman W, Berwick M, Bracci PM, Elwood JM, Ernstoff MS, Green A, Gruis NA, Holly EA, Ingvar C, Kanetsky PA, Karagas MR, Lee TK, Le Marchand L, Mackie RM, Olsson H, Østerlind A, Rebbeck TR, Reich K, Sasieni P, Siskind V, Swerdlow AJ, Titus L, Zens MS, Ziegler A, Gallagher RP, Barrett JH, Newton-Bishop J. Cancer Epidemiol Biomarkers Prev. 2015 May;24(5):817-24.

12. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. Gordon KB, Duffin KC, Bissonnette R, Prinz JC, Wasfi Y, Li S, Shen YK, Szapary P, Randazzo B, Reich K. N Engl J Med. 2015 Jul 9;373(2):136-44.

13. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K; UNCOVER-2 and UNCOVER-3 investigators. Lancet. 2015 Aug 8;386(9993):541-51.

14. Neutrophilic urticarial dermatosis (NUD) indicating Cryopyrin-associated periodic syndrome associated with a novel mutation of the NLRP3 gene. Herbert VG, Ahmadi-Simab K, Reich K, Böer-Auer A. J Eur Acad Dermatol Venereol. 2015 Mar 2. doi: 10.1111/jdv.13020. [Epub ahead of print]

15. [Cutaneous granulomatous reactions at botulinum neurotoxin A injection sites : First manifestation of systemic sarcoidosis]. Herbert VG, Blödorn-Schlicht N, Böer-Auer A, Getova V, Steinkraus V, Reich K, Breuer K. Hautarzt. 2015 Nov;66(11):863-6.

16. Severe ulcerative penile leishmaniasis - Importance of PCR-based diagnostics. Herbert VG, Böer-Auer A, Brandenburg A, Falk TM, Reiter-Owona I, Rockstroh JK, Reich K. J Infect. 2015 Jul;71(1):139-41.




17. Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: Results from the PHOENIX 2 study through 5 years of follow-up. Langley RG, Lebwohl M, Krueger GG, Szapary PO, Wasfi Y, Chan D, Hsu MC, You Y, Poulin Y, Korman N, Prinz JC, Reich K. The PHOENIX 2 Investigators. Br J Dermatol. 2015 May;172(5):1371-83.

18. Calcium spirulan derived from Spirulina platensis inhibits herpes simplex virus 1 attachment to human keratinocytes and protects against herpes labialis. Mader J, Gallo A, Schommartz T, Handke W, Nagel CH, Günther P, Brune W, Reich K. J Allergy Clin Immunol. 2016 Jan;137(1):197-203.

19. Influence of psoriasis on circulatory system function assessed in echocardiography. Milaniuk S, Pietrzak A, Mosiewicz B, Mosiewicz J, Reich K. Arch Dermatol Res. 2015 Dec;307(10):855-61.

20. European S3-Guidelines on the systemic treatment of psoriasis vulgaris - Update 2015 - Short version - EDF in cooperation with EADV and IPC. Nast A, Gisondi P, Ormerod AD, Saiag P, Smith C, Spuls PI, Arenberger P, Bachelez H, Barker J, Dauden E, de Jong EM, Feist E, Jacobs A, Jobling R, Kemény L, Maccarone M, Mrowietz U, Papp KA, Paul C, Reich K, Rosumeck S, Talme T, Thio HB, van de Kerkhof P, Werner RN, Yawalkar N. J Eur Acad Dermatol Venereol. 2015 Dec;29(12):2277-94.

21. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, Hu C, Stevens RM, Day RM, Gordon KB, Korman NJ, Griffiths CE. J Am Acad Dermatol. 2015 Jul;73(1):37-49.

22. Tildrakizumab (MK- 3222), an Anti- IL-23p19 Monoclonal Antibody, Improves Psoriasis in a Phase 2b Randomized Placebo- Controlled Trial. Papp K, Thaçi D, Reich K, Riedl E, Langley RG, Krueger JG, Gottlieb AB, Nakagawa H, Bowman EP, Mehta A, Li Q, Zhou Y, Shames R. Br J Dermatol. 2015 Oct;173(4):930-9.

23. Real World Skin Clearance Rates for Biologic Treatments In Patients With Moderate to Severe Plaque Psoriasis: Interim Results From A Large Prospective, Observational Study. Paul C, Bewley A, Girolomoni G, Reich K, Puig L, Lacour JP, Augustin M, Naldi L, Menter AM, Wade S, Viswanathan HN, Palmer K, Klekotka P, Woolley JM. Value Health. 2015 Nov;18(7):A429.




24. Früherkennung der Komorbidität bei Psoriasis: Konsensusempfehlungen der Nationalen Konferenz zur Versorgung der Psoriasis. Radtke MA, Mrowietz U, Feuerhahn J, Härter M, von Kiedrowski R, Nast A, Reich K, Strömer K, Wohlrab J, Augustin M. J Dtsch Dermatol Ges. 2015;(7):674-90.

25. Treatment goals in psoriasis routine care. Radtke MA, Reich K, Spehr C, Augustin M. Arch Dermatol Res. 2015;307(5):445-9

26. Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest. Reich K, Mrowietz U, Radtke MA, Thaci D, Rustenbach SJ, Spehr C, Augustin M. Arch Dermatol Res. 2015 Dec;307(10):875-83.

27. Evidence That a Neutrophil-Keratinocyte Crosstalk Is an Early Target of IL-17A Inhibition in Psoriasis. Reich K, Papp KA, Matheson RT, Tu JH, Bissonnette R, Bourcier M, Gratton D, Kunynetz RA, Poulin Y, Rosoph LA, Stingl G, Bauer WM, Salter JM, Falk TM,Blödorn-Schlicht NA, Hueber W, Sommer U, Schumacher MM, Peters T, Kriehuber E, Lee DM, Wieczorek GA, Kolbinger F, Bleul CC. Exp Dermatol. 2015 Jul;24(7):529-35.

28. Efficacy of a fixed combination of calcipotriol/betamethasone dipropionate topical gel in adult patients with mild to moderate psoriasis: blinded interim analysis of a phase IV, multicenter, randomized, controlled, prospective study. Reich K, Zschocke I, Bachelez H, de Jong EM, Gisondi P, Puig L, Warren RB, Mrowietz U; the TTOP study group. J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1156-63.

29. Exploration of SNP variants affecting hair colour prediction in Europeans. Söchtig J, Phillips C, Maroñas O, Gómez-Tato A, Cruz R, Alvarez-Dios J, de Cal MÁ, Ruiz Y, Reich K, Fondevila M, Carracedo Á, Lareu MV. Int J Legal Med. 2015 Sep;129(5):963-75.

30. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. Thaçi D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, Ziv M, Pinter A, Hugot S, You R, Milutinovic M. J Am Acad Dermatol. 2015 Sep;73(3):400-9.

31. Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey. van de Kerkhof PC, Reich K, Kavanaugh A, Bachelez H, Barker J, Girolomoni G, Langley RG, Paul CF, Puig L, Lebwohl MG. J Eur Acad Dermatol Venereol. 2015 Oct;29(10):2002-10.




32. Psoriasis inversa. Weisenseel P, Reich K. Hautarzt 2015;(6):408-12.

33. Physical activity and energy expenditure during depressive episodes of major depression. Wielopolski J, Reich K, Clepce M, Fischer M, Sperling W, Kornhuber J, Thuerauf N. J Affect Disord. 2015 Mar 15;174:310-6.

34. Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomes. Augustin M, Blome C, Costanzo A, Dauden E, Ferrandiz C, Girolomoni G, Gniadecki R, Iversen L, Menter A, Michaelis-Wittern K, Morita A, Nakagawa H, Reich K. Br J Dermatol. 2014;170(3):591-8.

35. Topicallong-termtherapyofpsoriasiswithvitaminD₃analogues,corticosteroidsandtheirtwocompound formulations: position paper on evidence and use in daily practice. Augustin M, Mrowietz U, Bonnekoh B, Rosenbach T, Thaçi D, Reusch M, Ardabili M, Reich K. J Dtsch Dermatol Ges. 2014;12(8):667-82.

36. Arzneimittelversorgung von Kindern mit Psoriasis in Deutschland. Augustin M, Reich K, Glaeske G, Kämpfe S, Radtke MA, Gerdau-Heitmann C, Schicktanz C, Schäfer I. J Dtsch Dermatol Ges. 2014;(8):751-5.

37. Deutsches Psoriasis-Register PsoBest: Zielsetzung, Methodik und Basisdaten. Augustin M, Spehr C, Radtke MA, Boehncke W-H, Luger T, Mrowietz U, Reusch M, Strömer K, Wozel G, v. Kiedrowski R, Rustenbach SJ, Purwins S, Reich K. J Dtsch Dermatol Ges. 2014;(1):48-58.

38. Expert recommendations: the use of the fixed combination calcipotriol and betamethasone dipropionate gel for the topical treatment of psoriasis. Daudén E, Bewley A, Lambert J, Girolomoni G, Cambazard F, Reich K. J Eur Acad Dermatol Venereol. 2014;28 Suppl 2:22-32.

39. Psoriasis-associated keratitis : Case report. Filev FS, Herbert VG, Lögering B, von Gruben V, Reich K, Klemm M. Ophthalmologe. 2014;111(12):1201-3.

40. Treatment of Psoriasis: Focus on Clinic-Based Management with Infliximab. Gottlieb B, Reich K. Am J Clin Dermatol. 2014;15(1):1-24.




41. Ulcerative keratitis in psoriasis: a rare variant of psoriatic ocular inflammatory disease. Herbert VG, Lögering B, von Gruben V, Filev F, Klemm M, Reich K. Br J Dermatol. 2014 Mar;170(3):746-8.

42. IL-17A: A Unique Pathway in Immune- Mediated Diseases: Psoriasis, Psoriatic Arthritis, and Rheumatoid Arthritis. Kirkham BW, Kavanaugh A, Reich K. Immunology. 2014;141(2):133-42.

43. Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis. Langenbruch A, Radtke MA, Krensel M, Jacobi A, Reich K, Augustin M. Br J Dermatol. 2014;171(5):1123-8.

44. Secukinumab in plaque psoriasis--results of two phase 3 trials. Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C; ERASURE Study Group; FIXTURE Study Group. N Engl J Med. 2014;371(4):326-38.

45. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. Lebwohl MG, Bachelez H, Barker J, Girolomoni G, Kavanaugh A, Langley RG, Paul CF, Puig L, Reich K, van de Kerkhof PC. J Am Acad Dermatol. 2014;70(5):871-81.

46. A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. Mrowietz U, de Jong EM, Kragballe K, Langley R, Nast A, Puig L, Reich K, Schmitt J, Warren RB. J Eur Acad Dermatol Venereol. 2014;28(4):438-53.

47. Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT). Paul C, Puig L, Kragballe K, Luger T, Lambert J, Chimenti S, Girolomoni G, Nicolas JF, Rizova E, Lavie F, Mistry S, Bergmans P, Barker J, Reich K; TRANSIT Investigators. Br J Dermatol. 2014;170(2):425-34.

48. Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial. Paul Reich K, Gottlieb AB, Mrowietz U, Philipp S, Nakayama J, Harfst E, Guettner A, Papavassilis C; CAIN457A2211 study group. J Eur Acad Dermatol Venereol. 2014;28(12):1670-5.




49. Treatment adherence: a hurdle for real-life effectiveness in psoriasis? Reich K, Daudén E. J Eur Acad Dermatol Venereol. 2014;28 Suppl 2:1-3.

50. Development of an adherence-enhancing intervention in topical treatment termed the topical treatment optimization program (TTOP). Reich K, Mrowietz U, Karakasili E, Zschocke I. Arch Dermatol Res. 2014;306(7):667-76.

51. German psoriasis registry PsoBest: objectives, methodology and baseline data. Strömer K, Wozel G, von Kiedrowski R, Rustenbach SJ, Purwins S, Reich K. J Dtsch Dermatol Ges. 2014;12(1):48-57.

52. [Paradoxical skin reactions under therapy with TNF-alpha antagonists]. Weisenseel P, Reich K. Z Rheumatol. 2014;72(5):423-8. German

53. Non-adherence and measures to improve adherence in the topical treatment of psoriasis. Zschocke I, Mrowietz U, Karakasili E, Reich K. J Eur Acad Dermatol Venereol. 2014;28 Suppl 2:4-9.

54. Assessing adherence factors in patients under topical treatment: development of the Topical Therapy Adherence Questionnaire (TTAQ). Zschocke I, Mrowietz U, Lotzin A, Karakasili E, Reich K. Arch Dermatol Res. 2014;306(3):287-97.

55. Drug supply for children with psoriasis in Germany. Augustin M, Reich K, Glaeske G, Kämpfe S, Radtke MA, Gerdau-Heitmann C, Schicktanz C, Schäfer I. J Dtsch Dermatol Ges. 2013;11(8):751-5. doi: 10.1111/ddg.12102.

56. Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis. Dirschka T, Radny P, Dominicus R, Mensing H, Brüning H, Jenne L, Karl L, Sebastian M, Oster-Schmidt C, Klövekorn W, Reinhold U, Tanner M, Gröne D, Deichmann M, Simon M, Hübinger F, Hofbauer G, Krähn-Senftleben G, Borrosch F, Reich K, Berking C, Wolf P, Lehmann P, Moers-Carpi M, Hönigsmann H, Wernicke-Panten K, Hahn S, Pabst G, Voss D, Foguet M, Schmitz B, Lübbert H, Szeimies RM; AK-CT002 Study Group; AK-CT003 Study Group. Br J Dermatol. 2013;168(4):825-36. doi: 10.1111/bjd.12158.




57. Granulomatöse Hautveränderungen an Botulinumtoxin A Injektionsstellen – Fremdkörperreaktion oder kutane Sarkoidose? Herbert VG, Blödorn-Schlicht N, Prager W, Getova V, Rosenberger G, Steinkraus V, Reich K, Breuer K. Allergo J. 2013;22(6):405.

58. Rational for statin use in psoriatic patients. Mosiewicz J, Pietrzak A, Chodorowska G, Trojnar M, Szepietowski J, Reich K, Rizzo M. Arch Dermatol Res. 2013;305(6):467-72.

59. An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals. Mrowietz U, Kragballe K, Reich K, Griffiths CE, Gu Y, Wang Y, Rozzo SJ. Br J Dermatol. 2013;168(2):374-80. doi: 10.1111/j.1365-2133.2012.11214.x.

60. Efficacy and safety of methantheline bromide (Vagantin(®)) in axillary and palmar hyperhidrosis: results from a multicenter, randomized, placebo-controlled trial. Müller C, Berensmeier A, Hamm H, Dirschka T, Reich K, Fischer T, Rzany B. J Eur Acad Dermatol Venereol. 2013;27(10):1278-84.

61. Barriers to the prescription of systemic therapies for moderate-to-severe psoriasis – a multinational cross-sectional study. Nast A, Mrowietz U, Kragballe K, de Jong EM, Puig L, Reich K, Warren RB, Werner R, Kopkow C, Schmitt J. Arch Dermatol Res. 2013;305(10):899-907.

62. National and multinational guidelines in Europe: results from an online survey on awareness of different national and European psoriasis guidelines. Nast A, Mrowietz U, Kragballe K, Puig L, Reich K, Warren RB, Schmitt J. Arch Dermatol Res. 2013;305(7):637-43

63. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Papp KA, Griffiths CE, Gordon K, Lebwohl M, Szapary PO, Wasfi Y, Chan D, Hsu MC, Ho V, Ghislain PD, Strober B, Reich K; PHOENIX 1 Investigators; PHOENIX 2 Investigators; ACCEPT Investigators. Br J Dermatol. 2013;168(4):844-54. doi: 10.1111/bjd.12214.

64. Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis. Reich K, Berking C, Wolf P, Lehmann P, Moers-Carpi M, Hönigsmann H, Wernicke-Panten K, Hahn S, Pabst G, Voss D, Foguet M, Schmitz B, Lübbert H, Szeimies RM; AK-CT002 Study Group; AK-CT003 Study Group. Br J Dermatol. 2013;168(4):825-36.




65. Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2). Reich K, Wozel G, Zheng H, van Hoogstraten HJ, Flint L, Barker J. Br J Dermatol. 2013;168(6):1325-34. doi: 10.1111/bjd.12404.

66. Efficacy and safety of fumaric acid esters in patients with psoriasis on medication for comorbid conditions – a retrospective evaluation (FACTS). Thaçi D, Weisenseel P, Philipp S, Rosenbach T, Rotterdam S, Augustin M, Neureither M, Reich K. J Dtsch Dermatol Ges. 2013;11(5):429-35. doi: 10.1111/ddg.12059.

67. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo. Dirschka T, Radny P, Dominicus R, Mensing H, Brüning H, Jenne L, Karl L, Sebastian M, Oster-Schmidt C, Klövekorn W, Reinhold U, Tanner M, Gröne D, Deichmann M, Simon M, Hübinger F, Hofbauer G, Krähn-Senftleben G, Borrosch F, Reich K, Berking C, Wolf P, Lehmann P, Moers-Carpi M, Hönigsmann H, Wernicke-Panten K, Helwig C, Foguet M, Schmitz B, Lübbert H, Szeimies RM; AK-CT002 Study Group. Br J Dermatol. 2012;166(1):137-46.

68. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. Gordon KB, Papp KA, Langley RG, Ho V, Kimball AB, Guzzo C, Yeilding N, Szapary PO, Fakharzadeh S, Li S, Hsu MC, Reich K. J Am Acad Dermatol. 2012;66(5):742-51.

69. Prospective validation of the „rhino conjunctivitis allergy-control-SCORE©“ (RC-ACS©). Häfner D, Reich K, Zschocke I, Lotzin A, Meyer H, Kettner J, Narkus A. Clin Transl Allergy. 2012;2(1):17. doi: 10.1186/2045-7022-2-17.

70. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab‘ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. Reich K, Ortonne JP, Gottlieb AB, Terpstra IJ, Coteur G, Tasset C, Mease P. Br J Dermatol. 2012;167(1):180-90.

71. An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. Reich K, Papp KA, Griffiths CE, Szapary PO, Yeilding N, Wasfi Y, Ott E, Hsu MC, Lebwohl M, Gordon KB; PHOENIX 1, PHOENIX 2, and ACCEPT investigators. J Drugs Dermatol. 2012;11(3):300-12.




72. No association of vitamin D metabolism-related polymorphisms and melanoma risk as well as melanoma prognosis: a case-control study. Schäfer A, Emmert S, Kruppa J, Schubert S, Tzvetkov M, Mössner R, Reich K, Berking C, Volkenandt M, Pföhler C, Schön MP, Vogt T, König IR, Reichrath J. Arch Dermatol Res. 2012;304(5):353-61. doi: 10.1007/s00403-012-1243-3.

73. Systemic treatment with corticosteroids in psoriasis--health care provision far beyond the S3-guidelines. Augustin M, Schäfer I, Reich K, Glaeske G, Radtke M. J Dtsch Dermatol Ges. 2011;9(10):833-8.

74. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Barker J, Hoffmann M, Wozel G, Ortonne JP, Zheng H, van Hoogstraten H, Reich K. Br J Dermatol. 2011;165(5):1109-17.

75. An open-label study assessing the safety and efficacy of alitretinoin in patients with severe chronic hand eczema unresponsive to topical corticosteroids. Dirschka T, Reich K, Bissonnette R, Maares J, Brown T, Diepgen TL. Clin Exp Dermatol. 2011;36(2):149-54.

76. A new instrument for the assessment of patient-defined benefit in the treatment of allergic rhinitis. Franzke N, Schäfer I, Jost K, Blome C, Rustenbach SJ, Reich K, Reusch M, Maurer M, Augustin M. Allergy. 2011;66(5):665-70.

77. Prospective validation of ‚Allergy-Control-SCORE(TM)‘: a novel symptom-medication score for clinical trials. Häfner D, Reich K, Matricardi PM, Meyer H, Kettner J, Narkus A. Allergy. 2011;66(5):629-36.

78. Time management and quality of life after change of therapy from topical treatment and/or phototherapy to Fumaderm® in patients with psoriasis. Kahl C, Neureither M, Reich K, Zschocke I. Akt Dermatol.2011;37(7):249-53.

79. Improvement of treatment-refractory atopic dermatitis by immunoadsorption: A pilot study. Kasperkiewicz M, Schmidt E, Frambach Y, Rose C, Meier M, Nitschke M, Falk TM, Reich K, Ludwig RJ, Zillikens D. J Allergy Clin Immunol. 2011;127(1):267-70.




80. The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials. Leonardi C, Papp K, Strober B, Reich K, Asahina A, Gu Y, Beason J, Rozzo S, Tyring S. Am J Clin Dermatol. 2011;12(5):321-37.

81. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. Maurer M, Altrichter S, Bieber T, Biedermann T, Bräutigam M, Seyfried S, Brehler R, Grabbe J, Hunzelmann N, Jakob T, Jung A, Kleine-Tebbe J, Mempel M, Meurer M, Reich K, Ruëff F, Schäkel K, Sengupta K, Sieder C, Simon JC, Wedi B, Zuberbier T, Mahler V, Staubach P. J Allergy Clin Immunol. 2011;128(1):202-9.

82. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, Franke J, Antoniou C, Arenberger P, Balieva F, Bylaite M, Correia O, Daudén E, Gisondi P, Iversen L, Kemény L, Lahfa M, Nijsten T, Rantanen T, Reich A, Rosenbach T, Segaert S, Smith C, Talme T, Volc-Platzer B, Yawalkar N. Arch Dermatol Res. 2011 ;303(1):1-10.

83. Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE. Ortonne JP, Chimenti S, Reich K, Gniadecki R, Sprøgel P, Unnebrink K, Kupper H, Goldblum O, Thaçi D. J Eur Acad Dermatol Venereol. 2011;25(9):1012-1020.

84. Efficacious and safe management of moderate to severe scalp seborrhoeic dermatitis using clobetasol propionate shampoo 0·05% combined with ketoconazole shampoo 2%: a randomized, controlled study. Ortonne JP, Nikkels AF, Reich K, Ponce Olivera RM, Lee JH, Kerrouche N, Sidou F, Faergemann J. Br J Dermatol. 2011;165(1):171-6.

85. Nail psoriasis as a severity indicator: results from the PsoReal study. Radtke MA, Langenbruch AK, Schäfer I, Herberger K, Reich K, Augustin M. Patient Related Outcome Measures. 2011;2:1-6.

86. Immunologic Effects and Tolerability Profile of In-Season Initiation of a Standardized-Quality Grass Allergy Immunotherapy Tablet: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial in Adults with Grass Pollen-Induced Rhinoconjunctivitis. Reich K, Gessner C, Kroker A, Schwab JA, Pohl W, Villesen H, Wüstenberg E, Emminger W. Clin Ther. 2011;33(7):828-40.




87. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Reich K, Langley RG, Lebwohl M, Szapary P, Guzzo C, Yeilding N, Li S, Hsu MC, Griffiths CE. Br J Dermatol. 2011;164(4):862-72.

88. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. Reich K, Langley RG, Papp KA, Ortonne JP, Unnebrink K, Kaul M, Valdes JM. N Engl J Med. 2011;365(17):1586-96.

89. Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results. Reich K, Schenkel B, Zhao N, Szapary P, Augustin M, Bourcier M, Guenther L, Langley RG. J Dermatolog Treat. 2011;22(6):337-47.

90. Relationship between methotrexate dosing and clinical response in patients with moderate to severe psoriasis: subanalysis of the CHAMPION study. Saurat JH, Langley RG, Reich K, Unnebrink K, Sasso EH, Kampman W. Br J Dermatol. 2011,165(2):399-406.

91. Epidemiology and comorbidity of psoriasis in children. Augustin M, Glaeske G, Radtke MA, Christophers E, Reich K, Schäfer I. Br J Dermatol. 2010;162(3):633-6.

92. Nail psoriasis in Germany: epidemiology and burden of disease. Augustin M, Reich K, Blome C, Schäfer I, Laass A, Radtke MA. Br J Dermatol. 2010;163(3):580-5.

93. Co-morbidity and age-related prevalence of psoriasis: Analysis of health insurance data in Germany. Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M. Acta Derm Venereol. 2010;90(2):147-51.

94. Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. Avouac J, Walker U, Tyndall A, Kahan A, Matucci-Cerinic M, Allanore Y; EUSTAR, Miniati I, Muller A, Iannone F, Distler O, Becvar R, Sierakowsky S, Kowal-Bielecka O, Coelho P, Cabane J, Cutolo M, Shoenfeld Y, Valentini G, Rovensky J, Riemekasten G, Vlachoyiannopoulos P, Caporali R, Jiri S, Inanc M,Zimmermann Gorska I, Carreira P, Novak S, Czirjak L, Oliveira Ramos F, Jendro M, Chizzolini C, Kucharz EJ, Richter J, Cozzi F, Rozman B, Mallia CM, Gabrielli A,Farge D, Kiener HP, Schöffel D, Airo P, Wollheim F, Martinovic D, Trotta F, Jablonska S, Reich K, et al. J Rheumatol. 2010;37(7):1488-501.




95. Replication of LCE3C-LCE3B CNV as a risk factor for psoriasis and analysis of interaction with other genetic risk factors. Hüffmeier U, Bergboer JG, Becker T, Armour JA, Traupe H, Estivill X, Riveira-Munoz E, Mössner R, Reich K, Kurrat W, Wienker TF, Schalkwijk J, Zeeuwen PL, Reis A. J Invest Dermatol. 2010;130(4):979-84.

96. Further association analysis of chr 6q22-24 suggests a role of IL-20RA polymorphisms in psoriasis. Kingo K, Mössner R, Traks T, Rätsep R, Raud K, Reimann E, Krüger U, Silm H, Vasar E, Reich K, Kõks S. J Dermatol Sci. 2010;57(1):71-3.

97. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: Rationale for dosing recommendations. Lebwohl M, Yeilding N, Szapary P, Wang Y, Li S, Zhu Y, Reich K, Langley RG, Papp KA. J Am Acad Dermatol. 2010;63(4):571-9.

98. How do regional factors influence psoriasis patient care in Germany? Radtke MA, Augustin J, Blome, C, Reich K, Rustenbach SJ, Schäfer I, Laass A, Augustin M. J Deutsch Ges Dermatol. 2010;8(7):516-24.

99. Skin and Nail Responses after 1 Year of Infliximab Therapy in Patients with Moderate-to-Severe Psoriasis: A Retrospective Analysis of the EXPRESS Trial. Reich K, Ortonne JP, Kerkmann U, Wang Y, Saurat JH, Papp K, Langley R, Griffiths CE. Dermatology. 2010;221(2):172-8.

100. Ustekinumab and marked clinical responses in patients with moderate to severe psoriasis. Reich K, Shakery K, Mrowietz U, Szapary PO, Wang Y, Hsu M-C, Langley RG. Psoriasis Forum. 2010;16(1):3-11.

101. Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial. Reich K, Signorovitch J, Ramakrishnan K, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM. J Am Acad Dermatol. 2010;63(6):1011-8.

102. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study. Szeimies RM, Radny P, Sebastian M, Borrosch F, Dirschka T, Krähn-Senftleben G, Reich K, Pabst G, Voss D, Foguet M, Gahlmann R, Lübbert H, Reinhold U. Br J Dermatol. 2010;163(2):386-94.




103. Long-term follow-up of photodynamic therapy with a self-adhesive 5-aminolaevulinic acid patch: 12 months data. Szeimies RM, Stockfleth E, Popp G, Borrosch F, Brüning H, Dominicus R, Mensing H, Reinhold U, Reich K, Moor AC, Stocker M, Ortland C, Brunnert M, Hauschild A. Br J Dermatol. 2010;162(2):410-4.

104. Health services research in psoriasis - The german approach. Augustin M, Reich K, Reusch M, Luger T, Franzke N, Schäfer I, Rustenbach SJ, Radtke MA. Dermatology. 2009;218(4):293-301.

105. A pooled analysis of melanocytic nevus phenotype and the risk of cutaneous melanoma at different latitudes. Chang YM, Newton-Bishop JA, Bishop DT, Armstrong BK, Bataille V, Bergman W, Berwick M, Bracci PM, Elwood JM, Ernstoff MS, Green AC, Gruis NA, Holly EA, Ingvar C, Kanetsky PA, Karagas MR, Marchand LL, Mackie RM, Olsson H, Osterlind A, Rebbeck TR, Reich K, Sasieni P, Siskind V, Swerdlow AJ, Titus-Ernstoff L, Zens MS, Ziegler A, Barrett JH. Int J Cancer. 2009;124(2):420-8.

106. Skin sclerosis is only of limited value to identify SSc patients with severemanifestations – an analysis of a distinct patient subgroup of the German Systemic Rheumatology (Oxford). Hanitsch LG, Burmester GR, Witt C, Hunzelmann N, Genth E, Krieg T, Lehmacher W, Melchers I, Meurer M, Müller-Ladner U, Schulze-Lohoff E, Becker M, Sunderkoetter C; DNSS centers, Riemekasten G. 2009;48(1):70-3. [Prof. Reich is a DNSS center]

107. Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies. Hauschild A, Stockfleth E, Popp G, Borrosch F, Brüning H, Dominicus R, Mensing H, Reinhold U, Reich K, Moor AC, Stocker M, Ortland C, Brunnert M, Szeimies RM. Br J Dermatol. 2009;160(5):1066-74.

108. Characterization of psoriasis susceptibility locus 6 (PSORS6) in patients with early onset psoriasis and evidence for interaction with PSORS1. Hüffmeier U, Lascorz J, Becker T, Schürmeier-Horst F, Magener A, Ekici AB, Endele S, Thiel CT, Thoma-Uszynski S, Mössner R, Reich K, Kurrat W, Wienker TF, Traupe H, Reis A. J Med Genet. 2009;46(11):736-44.

109. Genetic variants of the IL-23R pathway: association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritis. Hüffmeier U, Lascorz J, Böhm B, Lohmann J, Wendler J, Mössner R, Reich K, Traupe H, Kurrat W, Burkhardt H, Reis A. J Invest Dermatol. 2009;129(2):355-8.




110. Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo-controlled study. Mease PJ, Reich K. J Am Acad Dermatol. 2009;60(3):402-11.

111. Analysis of a functional serotonin transporter promoter polymorphism in psoriasis vulgaris. Mössner R, Stiens G, König IR, Schmidt D, Platzer A, Krüger U, Reich K. Arch Dermatol Res. 2009;301(6):443-7.

112. [„TRECID“, TNFalpha related chronic inflammatory diseases - a new multiple diseases bridging concept]. Müller-Ladner U, Alten R, Heiligenhaus A, Kekow J, Koletzko S, Mrowietz U, Ochsenkühn T, Radke M, Reich K, Rudwaleit M, Schreiber S. Dtsch Med Wochenschr. 2009;134(42):2132-6.

113. Evaluation of Quality of Care and Guideline-Compliant Treatment in Psoriasis. Development of a New System of Quality Indicators. Radtke MA, Reich K, Blome C, Kopp I, Rustenbach SJ, Schäfer I, Augustin M. Dermatology. 2009;219(1):54-8.

114. Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey. Radtke M, Reich K, Blome C, Rustenbach S, Augustin M. J Eur Acad Dermatol Venereol. 2009;23(6):683-91.

115. Wirksamkeit und Sicherheit des humanen monoklonalen Interleukin-12/23-Antikörpers Ustekinumab bei Patienten mit Psoriasis: Ergebnisse der randomisierten, doppel-blinden, plazebokontrollierten Phase-III-Studien PHOENIX 1 und PHOENIX 2. Reich K. Akt Dermatol. 2009;35(1/2):29-34.

116. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Reich K, Krüger K, Mössner R, Augustin M. Br J Dermatol. 2009;160(5):1040-7.

117. Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis. Reich K, Segaert S, Van de Kerkhof P, Durian C, Boussuge MP, Paolozzi L, Wajdula J, Boggs R. Dermatology. 2009;219(3):239-49.




118. Efficacy and safety of fumaric acid esters in the long-term treatment of psoriasis – a retrospective study (FUTURE). Reich K, Thaci D, Mrowietz U, Kamps A, Neureither M, Luger T. J Dtsch Dermatol Ges. 2009;7(7):603-11.

119. Distal and proximal interleukin (IL)-10 promoter polymorphisms associated with risk of cutaneous melanoma development: a case--control study. Schoof N, von Bonin F, König IR, Mössner R, Krüger U, Reich K, Berking C, Volkenandt M, Ziegler A, Böckmann L, Kuschal C, Thoms KM, Kube D, Emmert S. Genes Immun. 2009;10(6):586-90.

120. [Facial allergic contact dermatitis. Data from the IVDK and review of literature]. Schnuch A, Szliska C, Uter W; IVDK. Hautarzt. 2009;60(1):13-21. [Prof. Reich is a member of the IVDK]

121. Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors. Sunderkötter C, Herrgott I, Brückner C, Moinzadeh P, Pfeiffer C, Gerss J, Hunzelmann N, Böhm M, Krieg T, Müller-Ladner U, Genth E, Schulze-Lohoff E, Meurer M, Melchers I, Riemekasten G; DNSS Centers. Br J Dermatol. 2009;160(4):835-43. [Prof. Reich was one of the collaborators]

122. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. van de Kerkhof PC, Hoffmann V, Anstey A, Barnes L, Bolduc C, Reich K, Saari S, Segaert S, Vaillant L. Br J Dermatol. 2009;160(1):170-6.

123. Wirksamkeit einer kombinierten Therapie der atopischen Dermatitis mit Triclosan und Flumetasinpivalat (DuoGalen®Creme). Zschocke I, Lotzin A, Sebastian M, Dirschka T, Zielke A, Reich K. Akt Dermatol. 2009;35(12):496-501.

124. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Augustin M, Krüger K, Radtke MA, Schwippl I, Reich K. Dermatology. 2008;216(4):366-72.

125. Quality of psoriasis care in Germany - results of the national study PsoHealth 2007. Augustin M, Reich K, Reich C, Purwins S, Jeff Rustenbach S, Schäfer I, Radtke M. J Dtsch Dermatol Ges. 2008;6(8):640-5.




126. CD40 ligation during dendritic cell maturation reduces cell death and prevents interleukin-10-induced regression to macrophage-like monocytes. Haenssle H, Buhl T, Knudsen S, Krueger U, Rosenberger A, Reich K, Neumann C. Exp Dermatol. 2008;17(3):177-87.

127. Registry of the German Network for Systemic Scleroderma. The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Hunzelmann N, Genth E, Krieg T, Lehmacher W, Melchers I, Meurer M, Moinzadeh P, Müller-Ladner U, Pfeiffer C, Riemekasten G, Schulze-Lohoff E, Sunderkoetter C, Weber M, Worm M, Klaus P, Rubbert A, Steinbrink K, Grundt B, Hein R, Scharffetter-Kochanek K, Hinrichs R, Walker K, Szeimies RM, Karrer S, Müller A, Seitz C, Schmidt E, Lehmann P, Foeldvári I, Reichenberger F, Gross WL, Kuhn A, Haust M, Reich K, Böhm M, Saar P, Fierlbeck G, Kötter I, Lorenz HM, Blank N, Gräfenstein K, Juche A, Aberer E, Bali G, Fiehn C, Stadler R, Bartels V. Rheumatology (Oxford). 2008; 47(8):1185-92.

128. Association analysis of IL20RA and IL20RB genes in psoriasis. Kingo K, Mössner R, Rätsep R, Raud K, Krüger U, Silm H, Vasar E, Reich K, Kõks S. Genes Immun. 2008;9(5):445-51.

129. Adverse drug events in infliximib-treated patients compared with the general and psoriasis populations. Menter A, Reich K, Gottlieb AB, Bala M, Li S, Hsu MC, Guzzo C, Diels J, Gelfand JM. J Drugs Dermatol. 2008; 7(12):1137-46.

130. Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis: report on five cases. Mössner R, Thaci D, Mohr J, Pätzold S, Bertsch HP, Krüger U, Reich K. Arch Dermatol Res. 2008;300(3):101-5.

131. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K; PHOENIX 2 study investigators. Lancet. 2008 ;371(9625):1675-84.

132. The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab. Reich K, Griffiths CE. Arch Dermatol Res. 2008; 300(10):537-44.




133. Recommendations for the long-term treatment of psoriasis with infliximab: a dermatology expert group consensus. Reich K, Griffiths CE, Barker J, Chimenti S, Daudén E, Gianetti A, Gniadecki R, Katsambas A, Langley R, Mrowietz U, Ogilvie A, Ortonne JP, Reider N, Saurat JH. Dermatology. 2008;217(3):268-75.

134. Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis. Reich K, Sinclair R, Roberts G, Griffiths CE, Tabberer M, Barker J. Curr Med Res Opin. 2008; 24(5):1237-54.

135. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. Rich P, Griffiths CEM, Reich K, Nestle FO, Scher RK, Li S, Xu S, Hsu MC, Guzzo C. J Am Acad Dermatol. 2008;58(2):224-31.

136. Silica gel is as effective as acyclovir cream in patients with recurrent herpes labialis: results of a randomized, open-label trial. Zschocke I, Reich C, Zielke A, Reitmeier N, Reich K. J Dermatolog Treat. 2008;19(3):176-81.

137. Association analysis of IL19, IL20 and IL24 genes in palmoplantar pustulosis. Kingo K, Mössner R, Kõks S, Rätsep R, Krüger U, Vasar E, Reich K, Silm H. Br J Dermatol. 2007;156(4):646-52.

138. Variations of the melanocortin-1 receptor and the glutathione-S transferase T1 and M1 genes in cutaneous malignant melanoma. Mössner R, Anders N, König IR, Krüger U, Schmidt D, Berking C, Ziegler A, Brockmöller J, Kaiser R, Volkenandt M, Westphal GA, Reich K. Arch Dermatol Res. 2007;298(8):371-9.

139. Variations in the peroxisome proliferator-activated receptor-gamma gene and melanoma risk. Mössner R, Meyer P, Jankowski F, König IR, Kruger U, Kammerer S, Westphal G, Boettger MB, Berking C, Schmitt C, Brockmöller J, Ziegler A, Stapelmann H, Kaiser R, Volkenandt M, Reich K. Cancer Lett. 2007;246(1-2):218-23.

140. Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies). Niedermeier A, Eming R, Pfütze M, Neumann CR, Happel C, Reich K, Hertl M. Arch Dermatol. 2007;143(2):192-8.




141. TNF polymorphisms in psoriasis: association of psoriatic arthritis with the promoter polymorphism TNF*-857 independent of the PSORS1 risk allele. Reich K, Huffmeier U, König IR, Lascorz J, Lohmann J, Wendler J, Traupe H, Mössner R, Reis A, Burkhardt H. Arthritis Rheum. 2007;56(6):2056-2064.

142. Consistency of Infliximab response across subgroups of patients with psoriasis. Integrated results from randomized clinical trials. Reich K, Menter A, Plotnick M, Guzzo C, Li S, Gottlieb A. Psoriasis Forum. 2007; 13:21-7.

143. Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis. Reich K, Nestle FO, Wu Y, Bala M, Eisenberg D, Guzzo C, Li S, Dooley LT, Griffiths CE. Eur J Dermatol. 2007;17(5):381-6.

144. Krankheitskosten und Lebensqualität bei Patienten mit mittelschwerer bis schwerer Psoriasis vulgaris in Deutschland: eine multizentrische Studie. Schöffski O, Augustin M, Prinz J, Rauner K, Schubert E, Sohn S, Reich K. J Dtsch Dermatol Ges. 2007;5(3):209-19.

145. Evidence for susceptibility determinant(s) to psoriasis vulgaris in or near PTPN22 in German patients. Huffmeier U, Steffens M, Burkhardt H, Lascorz J, Schurmeier-Horst F, Stander M, Kelsch R, Baumann C, Kuster W, Mössner R, Reich K, Wienker TF, Traupe H, Reis A. J Med Genet. 2006;43(6):517-22.

146. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate- to-severe psoriasis: a randomized controlled trial. Reich K, Nestle FO, Papp K, Ortonne JP, Wu Y, Bala M, Evans R, Guzzo CA, Li S, Dooley LT, Griffiths CE. Br J Dermatol. 2006;154(6):1161-8.

147. Cost of moderate-to-severe plaque-psoriasis in Germany: a multicentre cost-of-illness study. Sohn S, Schoeffski O, Prinz J, Reich K, Schubert E, Waldorf K, Augustin M. Dermatology. 2006;212(2):137-44.

148. Assessment of 3 xeroderma pigmentosum group C gene polymorphisms and risk of cutaneous melanoma: a case-control study. Blankenburg S, König IR, Mössner R, Laspe P, Thoms KM, Krüger U, Khan SG, Westphal G, Berking C, Volkenandt M, Reich K, Neumann C, Ziegler A, Kraemer KH, Emmert S. Carcinogenesis. 2005;26(6):1085-90.




149. No association between three xeroderma pigmentosum group C and one group G gene polymorphisms and risk of cutaneous melanoma. Blankenburg S, König IR, Mössner R, Laspe P, Thoms KM, Krüger U, Khan SG, Westphal G, Volkenandt M, Neumann C, Ziegler A, Kraemer KH, Reich K, Emmert S. Eur J Hum Genet. 2005;13(2):253-5.

150. Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. Distler JH, Jungel A, Kowal-Bielecka O, Michel BA, Gay RE, Sprott H, Matucci-Cerinic M, Chilla M, Reich K, Kalden JR, Muller-Ladner U, Lorenz HM, Gay S, Distler O. Arthritis Rheum. 2005;52(3):856-64.

151. Association of TNF -238 and -308 promoter polymorphisms with psoriasis vulgaris and psoriatic arthritis but not with pustulosis palmoplantaris. Mössner R, Kingo K, Kleensang A, Krüger U, König IR, Silm H, Westphal GA, Reich K. J Invest Dermatol. 2005;124(1):282-4.

152. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE. Lancet. 2005;366(9494):1367-74.

153. Granulocyte colony-stimulating-factor-induced psoriasiform dermatitis resembles psoriasis with regard to abnormal cytokine expression and epidermal activation. Mössner R, Beckmann I, Hallermann C, Neumann C, Reich K. Exp Dermatol. 2004;13(6):340-6.

154. Variations in the genes encoding the peroxisome proliferator-activated receptors alpha and gamma in psoriasis. Mössner R, Kaiser R, Matern P, Kruger U, Westphal GA, Brockmöller J, Ziegler A, Neumann C, König IR, Reich K. Arch Dermatol Res. 2004;296(1):1-5.

155. A close look at autoimmune muscle disorders: association of Lambert-Eaton myasthenic syndrome with dermatomyositis. Mössner R, Tings T, Beckmann I, Neumann C, Paulus W, Reich K. Scand J Rheumatol. 2004;33(4):271-5.

156. The maturation-dependent production of interleukin-16 is impaired in monocyte-derived dendritic cells from atopic dermatitis patients but is restored by inflammatory cytokines TNF-alpha and IL-1beta. Reich K, Hugo S, Middel P, Blaschke V, Heine A, Neumann C. Exp Dermatol. 2004;13(12):740-7.




157. Expression of activation-induced, T cell-derived, and chemokine-related cytokine/lymphotactin and its functional role in rheumatoid arthritis. Blaschke S, Middel P, Dorner BG, Blaschke V, Hummel KM, Kroczek RA, Reich K, Benoehr P, Koziolek M, Muller GA. Arthritis Rheum. 2003;48(7):1858-72.

158. Association of allergic contact dermatitis with a promoter polymorphism in the IL16 gene. Reich K, Westphal GA, König IR, Mössner R, Krüger U, Ziegler A, Neumann C, Schnuch A. J Allergy Clin Immunol. 2003;112(6):1191-4.

159. Cytokine gene polymorphisms in atopic dermatitis. Reich K, Westphal GA, König IR, Mössner R, Schupp P, Gutgesell C, Hallier E, Ziegler A, Neumann Ch. Br J Dermatol. 2003;148(6):1237-41.

160. Cytokine gene polymorphisms in allergic contact dermatitis. Westphal GA, Schnuch A, Mössner R, König IR, Kränke B, Hallier E, Ziegler A, Reich K. Contact Dermatitis. 2003;48(2):93-8.

161. Quantitative RT-PCR: comparing real-time lightcycler technology with quantitative competitive RT-PCR. Blaschke V, Reich K, Blaschke S, Zipprich S, Neumann C. Biochemica. 2002;(1):6-8.

162. Agonists of peroxisome proliferator-activated receptor gamma inhibit cell growth in malignant melanoma. Mössner R, Schulz U, Krüger U, Middel P, Schinner S, László Fuzesi L, Neumann C, Reich K. J Invest Dermatol. 2002;119(3):576-82.

163. Evidence for a role of Langerhans cell-derived interleukin-16 in atopic dermatitis. Reich K, Hugo S, Middel P, Blaschke V, Heine A, Gutgesell C, Williams R, Neumann Ch. J Allergy Clin Immunol. 2002;109(4):681-7.

164. Promoter polymorphisms of the genes encoding tumor necrosis factor-alpha and interleukin-1beta are associated with different subtypes of psoriasis characterized by early and late disease onset. Reich KK, Mössner R, König IR, Westphal G, Ziegler A, Neumann Ch. J Invest Dermatol. 2002;118(1):155-63.

165. Wegenersche Granulomatose unter dem klinischen Bild einer Vasculitis allergica. Gräfe A, Vente C, Reich K, Hallermann Ch, Neumann Ch. Akt Dermatol. 2001;27(10):323-7.




166. Interleukin-16 expression and phenotype of interleukin-16 producing cells in Crohn‘s disease. Middel P, Reich K, Polzien F, Blaschke V, Hemmerlein B, Herms J, Korabiowska M, Radzun HJ. Gut. 2001;49(6):795-803.

167. Expression of the T-cell chemoattractant chemokine lymphotactin in Crohn‘s disease. Middel P, Thelen P, Blaschke S, Polzien F, Reich K, Blaschke V, Wrede A, Hummel KM, Gunawan B, Radzun HJ. Am J Pathol. 2001;159(5):1751-61.

168. Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal IL-8/CXCR2 pathway and normalization of keratinocyte maturation. Reich K, Garbe C, Blaschke V, Maurer C, Middel P, Westphal G, Lippert U, Neumann Ch. J Invest Dermatol. 2001;116(2):319-29.

169. EngagementofthehighaffinityIgEreceptor,Fc₃RI,stimulatestheproductionof IL-16 in Langerhans cell-like dendritic cells. Reich K, Heine A, Hugo S, Blaschke V, Middel P, Kaser A, Tilg H, Blaschke S, Gutgesell C, Neumann Ch. J Immunol. 2001;167(11):6321-9.

170. Rapid quantitation of proinflammatory and chemoattractant cytokine expression in small tissue samples and monocyte-derived dendritic cells, Validation of a new real-time RT-PCR technology. Blaschke V, Reich K, Blaschke S, Zipprich S, Neumann Ch. J Immunol Methods. 2000;246(1-2):79-90.

171. N-acetyltransferases 1 and 2 polymorphisms in para-substituted arylamine-induced contact allergy. Westphal GA, Reich K, Schulz TG, Neumann Ch, Hallier E, Schnuch A. Br J Dermatol. 2000;142(6):1121-7.

172. Homozygous gene deletions of the glutathione S-transferases M1 and T1 are associated with thimerosal sensitization. Westphal GA, Schnuch A, Schulz TG, Reich K, Aberer W, Brasch J, Koch P, Wessbecher R, Szliska C, Bauer A, Hallier E. Int Arch Occup Environ Health. 2000;73(6):384-8.

173. Expression of the CD4+ cell-specific chemoattractant interleukin-16 in mycosis fungoides. Blaschke V, Reich K, Middel P, Letschert M, Sachse F, Harwix S, Neumann Ch. J Invest Dermatol. 1999;113(4):658-63.

174. Graft-versus-host disease-like cutaneous immunophenotype and apoptotic keratinocyte death in paraneoplastic pemphigus. Reich K, Brinck U, Letschert M, Blaschke V, Dames K, Braess J, Wörmann B, Rünger TM, Neumann Ch. Br J Dermatol. 1999;141(4):739-46.




175. Combined analysis of polymorphisms of the tumor necrosis factor-alpha and interleukin-10 promoter regions and polymorphic xenobiotic metabolizing enzymes in psoriasis. Reich K, Westphal GA, Schulz TG, Müller M, Zipprich S, Fuchs Th, Hallier E, Neumann Ch. J Invest Dermatol. 1999;113(2):214-20.

176. Erosive mucosal lichen planus, response to topical treatment with tacrolimus. Vente C, Reich K, Rupprecht R, Neumann Ch. Br J Dermatol. 1999;140(2):338-42.

177. Genotype and phenotype of N-acetyltransferase 2 (NAT2): polymorphism in patients with contact allergy. Schnuch A, Westphal GA, Müller MM, Schulz TG, Geier J, Brasch J, Merk HF, Kawakubo Y, Richter G, Koch P, Fuchs Th, Gutgesell C, Reich K, Gebhardt M, Becker D, Grabbe J, Sziska C, Aberer W, Hallier E. Contact Dermatitis. 1998;38(4):209-11.

178. Isolating and maintaining highly polarized primary epithelial cells from normal human duodenum for growth as spheroid-like vesicles. Boxberger HJ, Meyer TF, Grausam MC, Reich K, Becker HD, Sessler MJ. In Vitro Cell Dev Biol Anim. 1997;35(7):536-45.

179. Mucocutaneous autoimmune syndrome following fludarabine therapy for low-grade non-Hodgkin´s lymphoma of B-cell type (B-NHL). Braess J, Reich K, Willert S, Strutz F, Neumann Ch, Hiddemann W, Wörmann B. Ann Hematol. 1997;75(5-6):227-30.

180. Local cellular immune response in Helicobacter pylori associated type B-gastritis – selective increase of CD4+ but not gamma/delta T-cells in the immune response to H. pylori antigens. Seifarth C, Deusch K, Reich K, Classen M. Z Gastroenterol. 1996;34(4):215-24.

181. Biased T-cell receptor V-beta repertoire of intestinal CD8+ T-cells in HIV-disease. Reich K, Dähne I, Endres N, Classen M, Deusch K. Adv Exp Med Biol. 1995;371B:1023-6.

182. Selective increase of CD4+ and CD25+ T-cells but not of gamma/delta T-cells in H pylori associated gastritis. Seifarth C, Funk A, Reich K, Dähne I, Classen M, Deusch K. Adv Exp Med Biol. 1995;371B:931-4.

183. Oligoclonality of human intestinal intraepithelial T-cells. Van-Kerckhove C, Russel GJ, Deusch K, Reich K, Bhan AK, DerSimonian H, Brenner MB. J Exp Med. 1992;175(1):57-63.




184. A major fraction of human intraepithelial lymphocytes simultaneously expresses the gamma/delta T-cell receptor, the CD8 accessory molecule and preferentially uses the V-delta 1 gene segment. Deusch K, Lüling F, Reich K, Classen M, Wagner H, Pfeffer K. Eur J Immunol. 1991;21(4):1053-9.

185. Phenotypic and functional characterization of human TCR gamma/delta+ intestinal intraepithelial lymphocytes. Deusch K, Pfeffer K, Reich K, Gstettenbauer M, Daum S, Lüling F, Classen M. Curr Top Microbiol Immunol. 1991;173:279-83.

reviews in peer-reviewed journals

1. Genetic diagnostics in inflammatory dermatoses--from insights into pathophysiology to individualized patient management. Reich K, Blödorn-Schlicht N, Falk TM. J Dtsch Dermatol Ges. 2013;11 Suppl 4:59-67. doi: 10.1111/ddg.12071_supp.

2. [Skin as manifestation organ for inflammatory rheumatic diseases]. Wollenhaupt J, Reich K. Z Rheumatol. 2013;72(5):422. doi: 10.1007/s00393-012-1126-1.

3. [Nail psoriasis--an ignored disorder. Pathogenesis, diagnosis and therapy]. Kahl C, Hansen B, Reich K. Hautarzt. 2012;63(3):184-91. German.

4. Neue Erkenntnisse zu Fumarsäureestern (Fumaderm®): Ergebnisse des 2. Experten-Workshops. Mrowietz U, Altmeyer P, Augustin M, Boehncke WH, Bonnekoh B, Frambach Y, Gambichler T, Ghoreschi K, Hertl M, Hund AC, Jacobi A, Kuhn A, Ludwig RJ, Luger T, Martin SF, Merk H, Norgauer J, Reich K, Rostami-Yazdi M, Sabat R, Schäkel K, Scharffetter-Kochanek K, Schön MP, Scola N, Sticherling M, Thaci D, Wilsmann-Theis D, Viehweg A, Wozel G, Zouboulis CC, Neureither M. J Dtsch Dermatol Ges. 2012 Dec;10 Suppl 8:1-15. doi: 10.1111/j.1610-0379.2012.08047.x.

5. The concept of psoriasis as a systemic inflammation: implications for disease management. Reich K. J Eur Acad Dermatol Venereol. 2012;26 Suppl 2:3-11.




6. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. Reich K, Burden AD, Eaton JN, Hawkins NS. Br J Dermatol. 2012 Jan;166(1):179-88.

7. In touch with psoriasis: a patient-centred approach to therapy. Langley R, Reich K. J Eur Acad Dermatol Venereol. 2011;25 Suppl 4:1-2.

8. [Neue Erkenntnisse zu Fumarsäureestern (Fumaderm®): Ergebnisse eines Experten-Workshops]. Mrowietz U, Adamczyk A, Augustin M, Boehncke WH, Bonnekoh B, Gambichler T, Hengge U, Lippert U, Ludwig RJ, Luger T, Merk HF, Norgauer J, Philipp S, Reich K, Röcken M, Rostami-Yazdi M, Schön MP, Scola N, Sticherling M, Thaci D, Viehweg A, Wallbrecht K, Wozel G, Zouboulis CC, Neureither M. J Dtsch Dermatol Ges. 2011 Sep;9 Suppl 4:1-13.

9. Strategies for improving the quality of care in psoriasis with the use of treatment goals--a report on an implementation meeting. Mrowietz U, Kragballe K, Nast A, Reich K. J Eur Acad Dermatol Venereol. 2011;25 Suppl 3:1-13.

10. In touch with psoriasis: topical treatments and current guidelines. Murphy G, Reich K. J Eur Acad Dermatol Venereol. 2011;25(Suppl 4):3-8.

11. [Psoriasis arthritis. An interdisciplinary challenge]. Radtke MA, Reich K, Beikert F, Augustin M. Hautarzt. 2011 Oct;62(10):779-90; quiz 791-2. German.

12. What is new in topical therapy for psoriasis? Reich K, Bewley A. J Eur Acad Dermatol Venereol. 2011;25(Suppl 4):15-20.

13. Genetic factors in contact allergy--review and future goals. Schnuch A, Westphal G, Mössner R, Uter W, Reich K. Contact Dermatitis. 2011;64(1):2-23.

14. Therapy of psoriasis in childhood and adolescence - a German expert consensus. Sticherling M, Augustin M, Boehncke WH, Christophers E, Domm S, Gollnick H, Reich K, Mrowietz U. J Dtsch Dermatol Ges. 2011;9(10):815-23.




15. Psoriasis: looking deeper into skin and nail diseases. Saurat JH, Reich K, editors. Dermatology 2010;221(Suppl1): 1-48.

16. Management of severe psoriasis with TNF antagonists. Adalimumab, etanercept and infliximab. Mössner R, Reich K. Curr Probl Dermatol. 2009;38:107-36.

17. Psoriasis – neue Erkenntnisse zur Pathogenese und Therapie. Mrowietz U, Reich K. Dtsch Arztebl Int. 2009;106(1-2):11-9.

18. [15 years of fumaderm: fumaric acid esters for the systemic treatment of moderately severe and severe psoriasis vulgaris]. Mrowietz U, Rostami-Yazdi M, Neureither M, Reich K. J Dtsch Dermatol Ges. 2009;7 Suppl 2:S3-16.

19. Approach to managing patient with nail psoriasis. Reich K. JEADV. 2009; 23(Suppl. 1):15-21.

20. Ustekinumab for the treatment of plaque psoriasis. Reich K. Expert Rev Dermatol.2009;4(5):443-53.

21. Ustekinumab. Reich K, Yasothan U, Kirkpatrick P. Nat Rev Drug Discov. 2009;8(5):355-6.

22. Psoriasis und das metabolische Syndrom: Viel mehr als eine Hautkrankheit. Shakery K, Mrowietz U, Reich K. Der Deutsche Dermatologe. 2009;57(5):307-11.

23. Outcome assessment and treatment goals. Finlay AY, Reich K. Expert Rev Dermatol. 2008; 3(4s):S39-S40.

24. Tumor necrosis factor antagonists in the therapy of psoriasis. Mössner R, Schön MP, Reich K. Clin Dermatol. 2008; 26(5):486-502.




25. Keynote lecture: psoriasis update. Reich K. Expert Rev Dermatol. 2008; 3(4s):S3-S9.

26. Psoriasis-Arthritis. Therapeutische Strategien: je früher desto besser. Radtke MA, Mössner R, Augustin M, Reich K. Der Deutsche Dermatologe. 2007;55(6):1-4.

27. Psoriasis-Arthritis. Klinik, Pathogenese und Diagnostik. Radtke MA, Mössner R, Augustin M, Reich K. Der Deutsche Dermatologe. 2007;55(5):327-33.

28. Teatment goals in psoriasis. Reich K, Mrowietz M. J Dtsch Dermatol Ges. 2007;5(7):566-574.

29. Use of fumaric acid esters in psoriasis. Roll A, Reich K, Böer A. Indian J Dermatol Venereol Leprol. 2007;73(2):133-7.

30. Psoriasis-Arthritis: eine interdisziplinäre Herausforderung. Boehncke WH, Friedrich M, Kaltwasser JP, Manger B, Mrowietz U, Reich K, Rosenbach T. Dtsch Arztebl. 2006;103(21):1455-61.

31. Evidenzbasierte Therapie des Raynaud-Syndroms. Distler M, Distler J, Ciurea A, Kyburz D, Müller-Ladner U, Reich K, Distler O. Z Rheumatol. 2006;65(4):285-9.

32. Biologics in der Therapie der Psoriasis: unerwünschte Effekte an der Haut. Mössner R, Reich K. Allergo J. 2006;15(7):492-500.

33. Infliximab in the treatment of psoriasis. Mössner R, Reich K. Expert Rev Dermatol. 2006;1(4):515-26.




34. Who is really in control of skin immunity under physiological circumstances – lymphocytes, dendritic cells or keratinocytes? Schröder JM, Reich K, Kabashima K, Liu FT, Romani N, Metz M, Kerstan A, Lee PHA, Loser K, Schön MP, Maurer M, Stoitzner P, Beissert S, Tokura Y, Gallo RL. Exp Dermatol. 2006;15(11):913-29.

35. Infliximab: Stellenwert in der Therapie der Psoriasis. Mössner R, Reich K. Hautarzt. 2005;56(9):831-8.

36. Pathogenetische Aspekte der Psoriasis-Arthritis. Mössner R, Reich K. Haut. 2005;(1): 19-24.

37. Biologics in der Therapie der Psoriasis. Reich K, Augustin M. Arzneimitteltherapie. 2005;23(12):384-97.

38. Enthesitis – Entzündung an den Sehnenansätzen: Mechanismus und Manifestation. Reich K, Mössner R. Pso Magazin. 2005;31(3):12-3.

39. The role of biologics in the management of psoriasis: a consensus paper by the Psoriasis Study Group, Arbeitsgemeinschaft Dermatologische Forschung. Boehncke WH, Friedrich M, Mrowietz U, Reich K, Rosenbach T, Sticherling M, Thaci D. J Dtsch Dermatol Ges. 2003;1(8):620-8.

40. Regulatory functions of IL-10 in the cutaneous immune system, a lesson to learn from experimental IL-10 therapy of inflammatory skin disease. Reich K. G Ital Dermatol Venereol. 2001;136:351-70.

41. Immunological aspects of inflammatory bowel disease. Deusch K, Reich K. Endoscopy. 1992;24(10):568-77.




Guidelines in peer-reviewed journals

1. Nail Psoriasis Delphi Expert Panel. Recommendations for the treatment of nail psoriasis in patients with moderate to severe psoriasis: a dermatology expert group consensus. Langley RG, Saurat JH, Reich K. J Eur Acad Dermatol Venereol. 2012 ;26(3):373-81.

2. S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update. Nast A, Boehncke WH, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Sammain A, Schlaeger M, Sebastian M, Sterry W, Streit V, Augustin M, Erdmann R, Klaus J, Koza J, Muller S, Orzechowski HD, Rosumeck S, Schmid-Ott G, Weberschock T, Rzany B. J Dtsch Dermatol Ges. 2012;10 Suppl 2:S1-95

3. German S3-guidelines on the treatment of psoriasis vulgaris (short version). Nast A, Boehncke WH, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Sammain A, Schlaeger M, Sebastian M, Sterry W, Streit V, Augustin M, Erdmann R, Klaus J, Koza J, Müller S, Orzechowski HD, Rosumeck S, Schmid-Ott G, Weberschock T, Rzany B. Arch Dermatol Res. 2012;304(2):87-113.

4. Methotrexate therapy in dermatology. Reich K, Domm S, Mrowietz U. J Dtsch Dermatol Ges. 2012;10(5):363-70.

5. [S3-guidelines for the treatment of psoriasis vulgaris Update 2011]. Nast A, Boehncke WH, Mrowietz U, Ockenfels HM, Philipp S, Reich K, RosenbachT, Sammain A, Schlaeger M, Sebastian M, Sterry W, Streit V, Augustin M, Erdmann R, Klaus J, Koza J, Müller S, Orzechowski HD, Rosumeck S, Schmid-Ott G, Weberschock T, Rzany B. J Dtsch Dermatol Ges. 2011;9 Suppl 2:S1-104.

6. Therapy with methotrexate in dermatology: guideline of the German Society for Dermatology. AWMF online. Reich K, Domm S, Mrowietz U. http://www.awmf.org/leitlinien/detail/ll/013-078.html (19-Aug-2011)

7. Scalp psoriasis. Wozel G, Klein E, Mrowietz U, Reich K, Sebastian M, Streit V. J Dtsch Dermatol Ges. 2011;9(1):70-4.




8. Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - update: „therapeutic options“ and „efalizumab“. Nast A, Augustin M, Boehncke WH, Klaus J, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Schlaeger M, Sebastian M, Sterry W, Streit V, Weisenseel P, Rzany B. J Dtsch Dermatol Ges. 2010;8(1):65-6.

9. Statement of the DDG and the BVDD on the EMEA recommendations regarding the use of raptiva [efalizumab]. Luger T, Reusch M, Reich K, Augustin M, Sterry W. J DtschDermatol Ges. 2009;7(4):291-2.

10. Cyclosporine therapy in dermatology. Mrowietz U, Klein CE, Reich K, Rosenbach T, Ruzicka T, Sebastian M, Werfel T. J Dtsch Dermatol Ges. 2009;7(5):474-9.

11. European S3-guidelines on the systemic treatment of psoriasis vulgaris. Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, Barker J, Bos JD,Burmester GR, Chimenti S, Dubertret L, Eberlein B, Erdmann R, Ferguson J, Girolomoni G, Gisondi P, Giunta A, Griffiths C, Hönigsmann H, Hussain M, Jobling R, Karvonen SL, Kemeny L, Kopp I, Leonardi C, Maccarone M, Menter A, Mrowietz U, Naldi L, Nijsten T, Ortonne JP, Orzechowski HD, Rantanen T, Reich K, Reytan N, Richards H, Thio HB, van de Kerkhof P, Rzany B. J Eur Acad Dermatol Venereol. 2009;23 Suppl 2:1-70.

12. Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris. Nast A, Kopp IB, Augustin M, Banditt KB, Boehncke WH, Follmann M, Friedrich M, Huber M, Kahl C, Klaus J, Koza J, Kreiselmaier I, Mohr J, Mrowietz U, Ockenfels HM, Orzechowski HD, Prinz J, Reich K, Rosenbach T, Rosumeck S, Schlaeger M, Schmid-Ott G, Sebastian M, Streit V, Weberschock T, Rzany B; Deutsche Dermatologische Gesellschaft (DDG); Berufsverband Deutscher Dermatologen (BVDD). J Dtsch Dermatol Ges.2007;5 Suppl 3:1-119.

13. German evidence-based guidelines for the treatment of Psoriasis vulagris (short version). Nast A, Kopp IB, Augustin M, Banditt KB, Boehncke WH, Follmann M, Friedrich M, Huber M, Kahl C, Klaus J, Koza J, Kreiselmaier I, Mohr J, Mrowietz U, Ockenfels HM, Orzechowski HD, Prinz J, Reich K, Rosenbach T, Rosumeck S, Schlaeger M, Schmid-Ott G, Sebastian M, Streit V, Weberschock T, Rzany B. Arch Dermatol Res. 2007;299(3):111-38.

14. Therapy of psoriasis-arthritis and psoriasis vulgaris with infliximab. Mrowietz U, Barth J, Boehncke WH, Reich K, Rosenbach T, Streit V, Wozel G. J Dtsch Dermatol Ges. 2006;4(5):444-7.




15. Therapy of psoriasis vulgaris with efalizumab. Mrowietz U, Barth J, Boehncke WH, Reich K, Rosenbach T, Streit V, Wozel G. J Dtsch Dermatol Ges. 2006;4(6):511-2.

16. S3-Guideline for the therapy of psoriasis vulgaris. Nast A, Kopp IB, Augustin M, Banditt KB, Boehncke WH, Follmann M, Friedrich M, Huber M, Kahl C, Klaus J, Koza J, Kreiselmaier I, Mohr J, Mrowietz U, Ockenfels HM, Orzechowski HD, Prinz J, Reich K, Rosenbach T, Rosumeck S, Schlaeger M, Schmid-Ott G, Sebastian M, Streit V, Weberschock T, Rzany B; German Society for Dermatology. J Dtsch Dermatol Ges. 2006;4 Suppl 2:S1-S126.

17. Evidenzbasierte (S3) Leitlinie zur Therapie der Psoriasis vulgaris. Nast A, Kopp IB, Augustin M, Banditt KB, Boehncke WH, Follmann M, Friedrich M, Huber M, Kahl C, Klaus J, Koza J, Kreiselmaier I, Mohr J, Mrowietz U, Ockenfels HM, Orzechowski HD, Prinz J, Reich K, Rosenbach T, Rosumeck S, Schlaeger M, Schmid-Ott G, Sebastian M, Streit V, Weberschock T, Rzany B. Der Deutsche Dermatologe. 2006;54(11):769-76.

18. Development of the evidence-based guidelines for psoriasis--a project of the German Dermatological Society (DDG). Follmann M, Sterry W, Rzany B, Boehncke WH, Weberschock T, Friedrich M, Mrowietz U, Kreiselmaier I, Ockenfels HM, Prinz J, Reich K, Mohr J, Rosenbach T, Schlaeger M, Sebastian M, Streit V. J Dtsch Dermatol Ges. 2005;3(9):678-89.

letters in peer-reviewed journals

1. Komplette Remission eines schweren chronisch rezidivierenden Angioödems unbekannter Ursache unter Omalizumab. von Websky A, Reich K, Steinkraus V, Breuer K. J Dtsch Dermatol Ges. 2013 ;11(7):676-8. doi: 10.1111/ddg.12075_suppl. 2. Anti-interleukin-17 monoclonal antibody ixekizumab in psoriasis. Reich K. N Engl J Med. 2012 Jul 19;367(3):274; author reply 275. doi: 10.1056/NEJMc1205835#SA1.

3. Treatment of severe psoriasis and psoriatic arthritis with leflunomide. Reich K, Hummel KM, Beckmann I, Mossner R, Neumann Ch. Br J Dermatol. 2002;146(2):335-6.




4. Clinical improvement of HIV-associated psoriasis parallels a reduction of HIV viral load induced by effective antiretroviral therapy. Fischer T, Schwörer H, Vente C, Reich K, Ramadori G. Aids. 1999;13(5):628-9.

5. Topical tacrolimus for pyoderma gangrenosum. Reich K, Vente C, Neumann Ch. Br J Dermatol. 1998;139(4):755-7.

6. Treatment of psoriasis with interleukin-10. Reich K, Brück M, Gräfe A, Vente C, Neumann Ch, Garbe C. J Invest Dermatol. 1998;111(6):1235-6.

reviews in non-peer-reviewed journals

1. Psoriasis - Arzneimittelsicherheit für Patienten muss gesichert sein. Radtke MA, Reich K. gpk. 2014;Sonderausgabe(1):45-8

2. Paradoxe Hautreaktionen unter Therapie mit TNF-alpha-Antagonisten. Weisenseel P, Reich K. Der Deutsche Dermatologe. 2013;61(8)522-7.

3. Kardiovaskuläre Erkrankungen bei Psoriasis vulgaris – Risikofaktoren und therapeutische Konsequenzen. Reich K. Spektrum der Dermatologie. 2012;2(1):6-7.

4. Therapie mit Methotrexat in der Dermatologie. Bei sorgfältiger Anwendung sicher und effektiv. Reich K, Domm S, Mrowietz U. Der Deutsche Dermatologe. 2012;60(3):176-81.

5. Psoriasis – State of the Art. Weisenseel P, Reich K. Kompendium Dermatologie. 2012;8(1):20-2.

6. Spondyloarthritis from the perspective of a dermatologist. Reich K. Rheumatol News Int. 2010; Suppl:9-10.




7. Psoriasis 2010 – State of the Art. Shakery K, Reich K. Kompendium Dermatologie. 2010;6(1):8-13.

8. Therapy of neurodermatitis (atopic dermatitis). Steinkraus V, Reich K, Breuer K. EADV Media InfoSheet 2010;(9):1-2.

9. Nagelpsoriasis – ein Fingerzeig. Shakery K, Reich K. ÄP Dermatologie Allergologie. 2009;(4):35-7.

10. Psoriasis 2009 – State of the Art. Shakery K, Reich K. Kompendium Dermatologie. 2009;5(1):2-4.

11. Psoriasis – Krankheitsbild und aktuelle Therapie. Shakery K, Reich K. Med Monatsschr Pharm. 2009;32(9):335-44.

12. Is your psoriasis patient a candidate for biologic therapy? Reich K. Skin & Allergy News. 2006;Suppl:10-1.

13. Die Haut als Spiegel des Immunsystems. Reich K. Der Dialysepatient. 2003;9:17-21.

editorial in non-peer-reviewed journal

1. Flagellanten-Dermatitis: toxische Reaktion oder T-Zell-vermittelte Spättypalergie? Szabo N, Reich K, Martin V, Breuer K. Allergologie. 2013;36(1):35-9.

2. Alitretinoin: ein neuer Wirkansatz für schwere chronische Handekzeme. Reich K. Thieme Case Report. 2009;1(1):p1.




books

1. Haut. Steinkraus V, Reich K, Schlolaut MA Köln: DuMont; 2011

2. Lebensqualität, Compliance und Empowerment bei Psoriasis. Augustin M, Reich K, Radtke MA, Dierks C. Bremen: UNI-MED; 2007.

book chapters

1. Ekzem, Psoriasis, kutane Infektionen, Akne und andere häufige Hautkrankheiten. Reich K (für die dt. Ausgabe). In: Longo et al., editors. Harrisons Innere Medizin, 18. Auflage. Berlin: ABW Wissenschaftsverlag; 2013.

2. Erythematöse, papulonodöse und erythematosquamöse Erkrankungen. Reich K, Mrowietz U. In: Braun-Falco, Plewig, Burgdorf Landthaler Dermatologie und Venerolgie. 6. Auflage

3. 14 Erythematöse, erythematosquamöse und pustulöse Erkrankungen. Reich K et al. In: Dirschka, T et al., editors. Klinikleitfaden Dermatologie, 3. Auflage. München: Urban & Fischer in Elsevier; 2010. p. 561-614.

4. Management of severe psoriasis with TNF antagonists. Adalimumab, Etanercept and Infliximab. Mössner R, Reich K. In: Yawalkar N, editors. Management of psoriasis (Current problems in dermatology ; 38). Basel: Karger; 2009. p. 107-136.

5. Dermatika. Reich K, Schmidt G. In: Estler CJ, Schmidt H, editors. Pharmakologie und Toxikologie, 6th ed. Stuttgart: Schattauer; 2006. p. 943-961.

6. Allergic contact dermatitis and atopic eczema. Schnuch A, Uter W, Reich K. In: Ring J, Przybilla B, Ruzicka T, editors. Handbook of atopic eczema, 2nd ed. Berlin: Springer; 2005. p. 176-99.




7. CD8+ gamma/delta cells (TCR1+CD8+) are a major population of human intraepithelial lymphocytes. Deusch K, Lüling F, Reich K, Classen M. In: Tsuchiya M et al., editors. Frontiers in mucosal immunology. Excerpta Medica International Congress Series. Amsterdam: Elsevier Science; 1991. p. 145-6.

8. T-Zellrezeptorrepertoire und Zytokinproduktion von humanen Darmlymphozyten. Deusch K, Pluschke G, Wagner F, Köhne G, Daum S, Reich K, Pfeffer K, Classen M. In: Seifert J et al., editors. Ökosystem Darm III. Berlin: Springer; 1991. p. 52-8.

Abstracts presented at international meetings published in peer reviewed journals

There are more than 200 abstracts published in peer reviewed journals with more than 100 listed in the ISI web of knowledge report.


dermatology is our passion. what is yours - tfscro.com · dermatology is our passion. what is ......

Documents